Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
Sponsor: Tectonic Operating Company, Inc.
Summary
The primary purpose of this study is to assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT). The study will also look at whether TX002100 reduces the need for blood or iron treatments, and whether it improves blood counts, such as hemoglobin levels.
Official title: An Open-label, Phase 1b Study to Assess the Safety, Tolerability, and Efficacy of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2027-01-31
Completion Date
2028-12-31
Last Updated
2026-10-07
Healthy Volunteers
No
Interventions
TX002100
Subcutaneous injection